Patents by Inventor Shengkan Jin

Shengkan Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nuclease-independent targeted gene editing platform and uses thereof
    Patent number: 11479793
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 25, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Highly Efficient DNA Base Editors Mediated By RNA-Aptamer Recruitment For Targeted Genome Modification And Uses Thereof
    Publication number: 20220290134
    Abstract: The present invention discloses a system for targeted gene editing and related uses. Also disclosed are related cells.
    Type: Application
    Filed: September 16, 2020
    Publication date: September 15, 2022
    Applicant: Rutgers,The State University of New Jersey
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Nuclease-Independent Targeted Gene Editing Platform and Uses Thereof
    Publication number: 20220267806
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 25, 2022
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Nuclease-independent targeted gene editing platform and uses thereof
    Patent number: 11390886
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 19, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Mitochondrial uncouplers for treatment of metabolic diseases and cancer
    Patent number: 10525021
    Abstract: 2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 7, 2020
    Assignee: Rutgers, the State University of New Jersey
    Inventors: Shengkan Jin, David J. Augeri, S. David Kimball, Peng Liu, Hanlin Tao, Xiangang Zeng
  • TARGETED GENE EDITING PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAK AND USES THEREOF
    Publication number: 20190330658
    Abstract: The present invention discloses systems for targeted gene editing and related uses.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 31, 2019
    Applicant: Rutgers, the State University
    Inventors: Shengkan JIN, Juan-Carlos COLLANTES
  • Mitochondrial uncouplers for treatment of metabolic diseases and cancer
    Patent number: 10227315
    Abstract: The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 12, 2019
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, David J. Augeri, Bin Cao, Hanlin Tao
  • Nuclease-Independent Targeted Gene Editing Platform and Uses Thereof
    Publication number: 20180327784
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Application
    Filed: July 15, 2016
    Publication date: November 15, 2018
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER
    Publication number: 20170334869
    Abstract: The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, Non-Alcholic Fatty Liver Disease (NAFLD), Non-Alcholic Steathohepatitis (NASH), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: Shengkan JIN, David J. AUGERI, Bin CAO, Hanlin TAO
  • NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER
    Publication number: 20170319516
    Abstract: 2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.
    Type: Application
    Filed: November 18, 2015
    Publication date: November 9, 2017
    Inventors: Shengkan JIN, David J. AUGERI, David S. KIMBALL, Peng LIU, Hanlin TAO, Xiangang ZENG
  • TREATMENT OF TYPE II DIABETES AND DIABETES-ASSOCIATED DISEASES WITH SAFE CHEMICAL MITOCHONDRIAL UNCOUPLERS
    Publication number: 20130231312
    Abstract: This application discloses methods for treating, preventing and/or alleviating the symptoms of type II diabetes and diabetes-related disorders or complications. The invention provides a novel approach to treating and managing disorders and symptoms related to elevated plasma glucose concentrations and insulin resistance, characterized by few side effects and low toxicity. In particular, the invention provides 2-hydroxy-benzoic anilide compounds and derivatives, and compositions thereof, which can control blood-glucose and increase insulin sensitivity by reducing plasma glucose concentration and cellular energy efficiency.
    Type: Application
    Filed: November 16, 2011
    Publication date: September 5, 2013
    Inventor: Shengkan Jin
  • INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR
    Publication number: 20110244059
    Abstract: The present invention relates to methods of mitigating, preventing or treating weight gain or obesity in patients by administering one or more autophagy inhibitors, thereby, preventing the differentiation process of pre-adipocyte cells into a mature adipocytes. Specifically, the present invention relates to the surprising discovery that autophagy is critical for the cellular remodeling required during pre-adipocyte differentiation into mature adipocyte. By targeting and inhibiting one or more mechanisms in autophagy, adipocyte maturation is also inhibited, thus, providing a novel a pathway to prevent, mitigate and/or treat weight gain, obesity and associated diseases, such as type II diabetes.
    Type: Application
    Filed: August 20, 2009
    Publication date: October 6, 2011
    Inventor: Shengkan Jin